Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years, Male or female
Pathologically confirmed Stage IV metastatic non-squamous non-small cell lung cancer (NSCLC) with documented positive EGFR sensitive mutation (EGFR 19del and L858R) and MRI confirmed brain metastases, diagnosed within 6 weeks prior to treatment initiation within baseline period
Received first-line osimertinib monotherapy during observation period
Upfront brain SRT during observation period
Baseline ECOG scored 0-2
Symptomatic brain metastases during baseline period\*
Complete imaging evaluation of systemic lesions (including brain MRI) during baseline period and before osimertinib treatment
At least 1 follow-up brain MRI during observation period
Baseline BM: ≤10 Brain metastases, largest tumor \<10 mL in volume and \<3 cm in longest diameter; total cumulative volume ≤15 ml \*Symptomatic brain metastases are defined as any neurological symptom in relation to the diagnosed BM, occurred within 30 days after brain metastases diagnosis.
You may not be if
Leptomeningeal metastases at stage IV NSCLC diagnosis
Whole brain radiotherapy treated BM during observation period
Patients received other systemic anti-tumor therapy in addition to osimertinib as 1L treatment during observation period
Secondary or multiple primary tumors at stage IV NSCLC diagnosis
Patients received any adjuvant targeted therapy after previous surgery
